LY30

LY30 is a parameter used in viscoelastic hemostasis testing, most commonly with thromboelastography (TEG). It quantifies the amount of fibrinolysis that occurs after the clot has reached its maximum strength. Specifically, LY30 represents the percentage decrease in clot amplitude 30 minutes after the maximum amplitude (MA) is achieved.

The calculation is based on the amplitudes observed over time. If MA is the maximum clot strength recorded, and A30 is the clot amplitude 30 minutes after MA, then LY30 = [(MA − A30) / MA] × 100. A higher LY30 indicates more pronounced fibrinolysis in the period following clot formation, while a low LY30 suggests relatively little fibrinolysis. Very high values can reflect hyperfibrinolysis; very low values may indicate fibrinolysis shutdown.

Clinical use of LY30 includes guiding hemostatic management in settings such as trauma, major surgery, obstetric hemorrhage, and liver disease. It helps assess the need for antifibrinolytic therapy (for example, tranexamic acid) and can be tracked alongside other thromboelastography parameters to tailor interventions. LY30 is interpreted in the context of the overall coagulation profile provided by the test, including MA and other fibrinolysis-related measures.

Limitations and considerations include pre-analytical variables, anticoagulants, and platform differences that affect LY30 values. The presence of heparin or inadequate neutralization can influence results, and reference ranges vary by protocol and device. Therefore, LY30 is most informative when interpreted together with other TE parameters rather than in isolation. Related measures include LY60 and MA.

---